0000000000680740
AUTHOR
Stefanie Voigt
Fractional exhaled nitric oxide is associated with more severe asthma
Fractional exhaled nitric oxide (FeNO) levels are used as a marker of airway inflammation. The aim of the present work was to evaluate a possible relationship between FeNO and parameters of asthma control and severity in different asthma phenotypes. FeNO was evaluated in 200 asthma patients (37% male, mean age ± SD 54±15 years, 19% controlled (GINA), 30% treated with oral corticosteroids (OCS), median FEV1 (interquartile range) 2,05 L (1,49-2,70), 74% pred. (56-90%)), together with other asthma characteristics (lung function, asthma control, allergies, serum IgE, serum ECP, and blood eosinophils). Patients with poorly controlled asthma had significantly higher FeNO values (ACQ-5≥1.5 vs. 70%…
Measurement of exhaled nitric oxide: comparison of 3 different analyzers
Exhaled nitric oxide (FeNO) is used as a surrogate marker to monitor airway inflammation. Aim of this study was to compare the new FeNO analyzer Vivatmo pro from Bosch (BV) with the Niox Vero from Circassia (CN) and the CLD from Ecomedics (EC). In 106 asthma patients (median age 54 years (range 20-87), 60 % female, median ACT of 16, 85 % on inhaled corticosteroids (mean 1300 μg BDP), 36 % on therapy with biologics) 2 FeNO measurements per patient and per device were performed using each analyzer in a random sequence according to the ATS / ERS guidelines. Additionally, the success rate to achieve a valid NO value was evaluated. 70 % of the patients had FeNO values In conclusion, for the rang…
Real-life effectiveness of anti-IL-5(-receptor) antibody treatment in patients with severe eosinophilic asthma
In patients with uncontrolled, severe eosinophilic asthma treatment with anti-IL-5(-receptor) (anti-IL5(R)) antibodies is a promising therapeutic approach. Results of clinical trials demonstrate a very good effectiveness and safety profile of these drugs. However, there is limited data on real-life effectiveness because the drugs have been approved for just a few years. Aim of the present study was to evaluate the real-life effectiveness of the anti-IL5(R) antibodies mepolizumab, reslizumab and benralizumab in severe eosinophilic asthma shortly after approval in Germany. In 119 patients (n=44 male, mean age 54±14 yrs., BMI 27.5±6.2, FEV1 1.9±0.8L (64±21%), 5±3 exacerbations in the last 12 m…
Measurement of Fractional Exhaled Nitric Oxide: Comparison of Three Different Analysers
<b><i>Background:</i></b> Fractional exhaled nitric oxide (FeNO) is a surrogate marker for airway inflammation, supporting the diagnostic pathway and treatment decisions for asthma patients. <b><i>Objectives:</i></b> Aim of this study was to compare the new analyser Vivatmo pro (Bosch, BV) with NIOX VERO (Circassia, CN) and CLD (Ecomedics, EC). <b><i>Methods:</i></b> In 100 asthmatics (median 53 years [range 20–87], 62% female, 86% on inhaled corticosteroids [mean 1,300 μg beclomethasone dipropionate or equivalent], 35% treated with biologics) 2 FeNO measurements per device were performed. Additionally, the success rate…